Table 3. Patient demographics, tumor characteristics, and treatment groups.
Patient and tumor factors | Number of patients (% of total) (n = 90) | |
---|---|---|
Sex | Male | 72 (80%) |
Female | 18 (20%) | |
Primary subsite | Preauricular | 15 (17%) |
Scalp | 15 (17%) | |
Temple | 11 (12%) | |
Forehead | 10 (11%) | |
Cheek | 9 (10%) | |
Ear | 8 (9%) | |
Eyebrow | 8 (9%) | |
Postauricular | 5 (6%) | |
Nose | 4 (4%) | |
Midface | 3 (3%) | |
Lip | 1 (1%) | |
Neck | 1 (1%) | |
Histology | Squamous cell carcinoma | 68 (76%) |
Basal cell carcinoma | 15 (17%) | |
Other | 7 (8%) | |
Prior treatments | Surgery | 74 (82%) |
Radiation | 15 (17%) | |
Immunosuppression | Yes | 18 (20%) |
No | 72 (80%) | |
Orbital invasion | Yes | 25 (28%) |
No | 65 (72%) | |
Treatment groups | Surgery alone | 15 (17%) |
Radiation alone | 6 (7%) | |
Surgery and radiation | 69 (77%) | |
Complications | 30-d mortality | 2 (2%) |
Stroke | 1 (1%) | |
Myocardial infarction | 2 (2%) | |
CSF leak | 5 (6%) | |
Reconstructive flap failure | 2 (2%) | |
Hematoma | 4 (4%) |
Abbreviation: CSF, cerebrospinal fluid.